Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peposertib - Merck KGaA

Next Previous
Drug Profile

Peposertib - Merck KGaA

Alternative Names: M-3814; MSC-2490484A; Nedisertib

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); Telix Pharmaceuticals; University of Kentucky
  • Class Antineoplastics; Halogenated hydrocarbons; Morpholines; Pyridazines; Quinazolines; Small molecules
  • Mechanism of Action DNA-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Sarcoma
  • Preclinical Neuroblastoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Glioblastoma; Neuroendocrine tumours

Most Recent Events

  • 12 Jun 2025 Pharmacodynamics data from ex vivo studies in Chronic lymphocytic leukemia presented at the 30th Congress of the European Haematology Association (EHA-2025)
  • 30 May 2025 Updated efficacy and adverse events data from a phase I/II trial in Prostate cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 23 Oct 2024 Adverse events and efficacy data from phase I/II trial in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR) (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top